Results 251 to 260 of about 128,160 (300)

Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis. [PDF]

Brain Behav
Raza H, Nizam B, Padaniya A, Farid MA, Nabi A, Hasan MQ, Salih M, Patel AH, Inam N, Rehman MEU, Khan U, Alsubari AMA.   +11 more
europepmc   +1 more source

Neurology: Parkinson’ Disease

Revista de Medicina y Cine / Journal of Medicine and Movies, 2016
José Elías GARCÍA SÁNCHEZ, Enrique GARCÍA SÁNCHEZ, María Lucila MERINO MARCOS   +2 more
doaj  

Effects of a Soft Robotic Exoskeleton for Gait Training on Clinical Outcomes in Patients With Parkinson Disease: Randomized Controlled Pilot Study. [PDF]

J Med Internet Res
Bu S, Luo X, Li S, Shi Y, Jin L, Zhao Q.
europepmc   +1 more source

Orthopedic manifestations, complications, and outcomes for arthroplasty in patients with Parkinson disease. [PDF]

Bull Hosp Jt Dis (2013)
Papalia AG, Romeo PV, Khabie L, Alben MG, Virk MS, Zuckerman JD.   +5 more
europepmc   +1 more source

Parkinson disease [PDF]

Nature Reviews Disease Primers, 2017
Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age. Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease.
Werner Poewe, Klaus Seppi, Caroline M Tanner   +2 more
exaly   +4 more sources